country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-112765

Copy Link Print Information

AtuFECT01

AtuFECT01 is a cationic lipid component. AtuFECT01 is used to construct AtuPLEX/Atu027 Lipid nanoparticles. AtuFECT01 improves cellular uptake and endosomal escape of siRNA in AtuFECT01-based lipoplexes. Formulation of AtuFECT01 with Tie2 siRNA into lipoplexes reduces Tie2 expression in mouse lung.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 869094-19-9
Formel: C₄₃H₉₀Cl₃N₇O₂
Molecular Weight:843.58

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

AtuFECT01 Chemical Structure

CAS. Nr.: 869094-19-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

AtuFECT01-based siRNA-lipoplexes (1-50 nM; 48 h) inhibit PKN3 protein expression in HeLa cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AtuFECT01-based siRNA-lipoplex (1.88 mg/kg siRNA and 14.5 mg/kg lipid; i.v. via tail vein; once daily; four consecutive days) reduces endothelial CD31 and Tie2 mRNA/protein in lung, heart, and liver and lowers serum soluble Tie2 in healthy nude mice^[2].
DACC/AtuFECT01 lipoplexes (0.75-3 mg siRNA/kg; intravenous bolus; single or once daily; 3 consecutive days) mediate dose-dependent, lung endothelial-specific knockdown of Tie-2, CD31, VEGFR2, VE-Cadherin, and BMPR-2 in C57Bl/6j healthy mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Hsd:NMRI-nu/nu nude (male, 9 weeks)^[2]
Dosage:

1.88 mg/kg siRNA and 14.5 mg/kg lipid
Administration:

i.v. via tail vein; once daily; four consecutive days
Result:

Reduced Tie2 mRNA in lung, heart, and liver after siRNA^Tie2-lipoplex administration.
Reduced CD31 mRNA in lung, heart, and liver after siRNA^CD31-lipoplex administration.
Reduced Tie2 mRNA more prominently than CD31 mRNA in liver.
Inhibited both target genes similarly in lung and heart.
Reduced Tie2 protein in all three analyzed organs after siRNA^Tie2-lipoplex administration.
Reduced CD31 protein in lung and heart after siRNA^CD31-lipoplex administration.
Reduced serum soluble Tie2 on day 5 in siRNA^Tie2-lipoplex-administered mice compared with sucrose, siRNA^PTEN, and siRNA^CD31 control cohorts.
Observed no suppression of endothelial gene expression in kidney and spleen.

Related Protocols :

Chemical Information

CAS. Nr. 869094-19-9
Molecular Weight 843.58
Formel C₄₃H₉₀Cl₃N₇O₂
SMILES

N=C(N)NCCC[C@H](N)C(NC[C@H](N)C(N(CCCCCCCCCCCCCCCC)CCCCCCCC/C=C\CCCCCCCC)=O)=O.Cl.Cl.Cl
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Miller AD, et al. Delivery of RNAi therapeutics: work in progress. Expert review of medical devices. 2013 Nov;10(6):781-811. [Content Brief]

[2]. Santel A, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene therapy. 2006 Aug;13(16):1222-34.

[3]. Fehring V, et al. Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC. Molecular therapy : the journal of the American Society of Gene Therapy. 2014 Apr;22(4):811-20.

[4]. Hattori Y, et al. Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex. Journal of drug targeting. 2019 Feb;27(2):217-227. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen